← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems
imipenem, cilastatin and relebactam
J01DH56
Forms & Strengths
- Imipenem 500mg, Cilastatin 500mg, Relebactam 250mg vial for injection
- Imipenem 1000mg, Cilastatin 1000mg, Relebactam 500mg vial for injection
Adult Dosing
- 1.25g (imipenem 1000mg, cilastatin 1000mg, relebactam 500mg) IV every 6 hours for complicated UTI
- 1.25g (imipenem 1000mg, cilastatin 1000mg, relebactam 500mg) IV every 8 hours for complicated intra-abdominal infection
- 1.25g (imipenem 1000mg, cilastatin 1000mg, relebactam 500mg) IV every 6 hours for hospital-acquired bacterial pneumonia
Pediatric Dosing
- Pediatric use is not established
- Safety and efficacy not established in patients under 18 years of age
Indications
- Complicated urinary tract infections (cUTI) including pyelonephritis
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Complicated intra-abdominal infections (cIAI)
Mechanism of Action
- Imipenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis
- Cilastatin inhibits renal dehydropeptidase, an enzyme that inactivates imipenem
- Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by beta-lactamases
Contraindications
- Hypersensitivity to imipenem, cilastatin, relebactam, or other carbapenems
- History of anaphylactic reactions to beta-lactams
Adverse Reactions
- Hypersensitivity reactions (anaphylaxis, angioedema, Stevens-Johnson syndrome)
- Nausea, vomiting, diarrhea, abdominal pain
- Thrombophlebitis, phlebitis
- Seizures, delirium
Drug Interactions
- Valproic acid: decreased valproic acid levels, increased risk of seizures
- Ganciclovir: increased risk of seizures
- Probenecid: increased imipenem levels
Curated Content: Needs Vetting Before Put to Clinical Use